Global Immuno-Oncology Drugs Market Set for Strong Expansion, Reaching $226.31 Billion With 13.5% CAGR by 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the immuno-oncology drugs market from 2026–2035 with trusted insights from The Business Research Company
What was the valuation of the Immuno-Oncology Drugs Market in 2026, and what figure is it projected to hit by 2030?
The immuno-oncology drugs market size has experienced rapid expansion in recent years. It is projected to increase from $120.37 billion in 2025 to $136.15 billion in 2026, with a compound annual growth rate (CAGR) of 13.1%. The growth in prior periods can be attributed to the limited availability of immuno-oncology drugs, a prevailing reliance on conventional chemotherapy, the increasing prevalence of cancers such as melanoma and lung cancer, expanding oncology-focused research initiatives, and early regulatory approvals for monoclonal antibodies.
The immuno-oncology drugs market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $226.31 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.5%. Factors contributing to this growth during the forecast period include advancements in bispecific antibodies and oncolytic virus therapies, the widening scope of personalized immunotherapy solutions, increased capital allocation towards adoptive cell transfer therapies, escalating healthcare spending for cancer treatments, and the incorporation of digital platforms for patient oversight and clinical research. Key trends observed during this period encompass the growing acceptance of immune checkpoint inhibitors across diverse cancer types, the expanded development of cancer vaccines and adoptive cell therapies, a heightened emphasis on individualized immuno-oncology treatments, the proliferation of hospital and ambulatory surgical center-based immunotherapy initiatives, and an increase in clinical trials and research pertaining to monoclonal antibodies.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp
Which Drivers Are Affecting Market Participation In The Immuno-Oncology Drugs Market?
The rising prevalence of cancer cases is projected to fuel the expansion of the immuno-oncology drugs market moving forward. Cancer is a condition where abnormal cells multiply uncontrollably, potentially spreading and impairing normal bodily functions. The uptick in cancer diagnoses is driven by factors such as an aging demographic, changes in lifestyle, and advancements in cancer screening methods. Immuno-oncology drugs support this trend by stimulating the body’s immune system to target and eliminate cancer cells, thereby offering more effective and precise treatment solutions. For instance, in 2023, according to Cancer Australia, a government agency based in Australia, an estimated 164,694 new cancer cases were identified and 51,269 deaths occurred, with prostate, breast, melanoma, colorectal, and lung cancers being the most frequently diagnosed, while rare cancers accounted for about one-third of diagnoses and 42% of deaths. Therefore, the increasing incidence of cancer cases is a primary driver for the growth of the immuno-oncology drugs market.
What Segment Categories Are Covered In The Immuno-Oncology Drugs Market?
The immuno-oncology drugs market covered in this report is segmented –
1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Other Types
2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application
3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors
3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies
4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
5) By Other Types: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies
What Long-Term Trends Are Expected To Shape The Future Of The Immuno-Oncology Drugs Market?
Leading firms within the immuno-oncology drugs market are engaging in collaborations to create and commercialize a new checkpoint antibody, with the goal of improving the efficacy of cancer treatments. These strategic alliances drive innovation through interdisciplinary knowledge sharing, which expedites the advancement of combination therapies, individualized treatments, and innovative drug delivery systems. For example, in March 2023, BioNTech SE, a company based in Germany, formed a partnership with OncoC4 Inc, a US-based pharmaceutical company, to jointly develop and market a checkpoint antibody, specifically the anti-CTLA-4 monoclonal antibody candidate identified as ONC-392. This collaboration seeks to broaden the available cancer treatment options across a range of solid tumor indications.
Which Leading Companies Dominate The Immuno-Oncology Drugs Market Share?
Major companies operating in the immuno-oncology drugs market are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals.
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report
How Does The Immuno-Oncology Drugs Market Perform Across Major Global Regions?
North America was the largest region in the immuno-oncology drugs market in 2025. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Immuno-Oncology Drugs Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3455&type=smp
Browse Through More Reports Similar to the Global Immuno-Oncology Drugs Market 2026, By The Business Research Company
Veterinary Laboratory Testing Services Market Report 2026
Dermatitis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report
Veterinary Diagnostic Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
